ARMP
Armata Pharmaceuticals Inc
3.50$
+6.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -12.8% | +22.4% | -10.0% | -9.3% | -12.0% | +0.9% | -7.4% | +10.8% | -14.1% | -9.2% | +28.9% | |
| – | -47.7% | +117.8% | -25.9% | -27.6% | -49.5% | +16.4% | -42.9% | +125.1% | -37.0% | -44.3% | +356.7% | |
| – | -43.6% | +180.0% | -30.3% | -35.1% | -45.8% | +25.8% | -63.0% | +240.9% | -41.1% | -45.3% | +403.8% | |
| – | -43.6% | +180.0% | -30.3% | -35.1% | -45.8% | +25.8% | -63.0% | +240.9% | -41.1% | -45.3% | +403.8% | |
| – | -60.4% | -49.0% | -27.5% | +78.7% | -66.5% | -68.0% | +810.9% | -65.0% | -37.8% | -90.0% | +5,287.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | +4.2% | +35.6% | -12.7% | -3.4% | -9.9% | +4.9% | +6.6% | +23.2% | +59.6% | +29.1% | -15.8% | |
| – | -24.8% | +568.5% | +11.9% | -4.0% | -59.2% | +129.1% | +8.6% | +16.5% | -93.6% | +3.1% | +2,611.3% | |
| – | -29.5% | +998.7% | +13.3% | -4.7% | -61.4% | +147.2% | +8.9% | +16.1% | -96.6% | +0.6% | +5,258.3% | |
| – | -58.0% | +29.8% | -15.3% | +4.1% | -57.8% | +28.1% | -1.6% | +32.6% | -28.0% | -28.3% | +80.8% | |
| – | +14.3% | -57.0% | – | – | – | – | – | – | +1,585.8% | +33.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.1% | +61.2% | -37.9% | +63.3% | -38.8% | +0.0% | +0.1% | +0.3% | +0.5% | +69.8% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.